Merck

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Merck 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRK

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. 

CEO
Robert M. Davis
CEORobert M. Davis
Employees
75,000
Employees75,000
Headquarters
Rahway, New Jersey
HeadquartersRahway, New Jersey
Founded
1891
Founded1891
Employees
75,000
Employees75,000

MRK Key Statistics

Market cap
211.77B
Market cap211.77B
Price-Earnings ratio
13.07
Price-Earnings ratio13.07
Dividend yield
3.82%
Dividend yield3.82%
Average volume
10.08M
Average volume10.08M
High today
$84.89
High today$84.89
Low today
$83.02
Low today$83.02
Open price
$83.28
Open price$83.28
Volume
10.76M
Volume10.76M
52 Week high
$109.92
52 Week high$109.92
52 Week low
$73.31
52 Week low$73.31

MRK News

Investor's Business Daily 23h
Pfizer, Merck And Astellas Have An 'Enormous New Hope' For Bladder Cancer Patients

Pharma titans Merck (MRK), Pfizer (PFE) and Astellas Pharma (ALPMY) are delivering an "enormous new hope" for patients with an aggressive form of bladder cancer...

Pfizer, Merck And Astellas Have An 'Enormous New Hope' For Bladder Cancer Patients
Simply Wall St 1d
Merck Valuation in Focus After Groundbreaking KEYTRUDA Trial Results for Ovarian Cancer

Merck (MRK) revealed that its Phase 3 KEYNOTE-B96 trial met a key secondary endpoint, as KEYTRUDA with chemotherapy improved overall survival in platinum-resist...

Merck Valuation in Focus After Groundbreaking KEYTRUDA Trial Results for Ovarian Cancer
Benzinga 3d
Merck's Keytruda Plus Chemo Regimen Shows Overall Survival Benefit In Recurrent Ovarian Cancer Patients

Merck & Co. Inc. (NYSE:MRK) announced data from the Phase 3 KEYNOTE-B96 trial (ENGOT-ov65) of Keytruda (pembrolizumab) in combination with chemotherapy (paclita...

Merck's Keytruda Plus Chemo Regimen Shows Overall Survival Benefit In Recurrent Ovarian Cancer Patients

Analyst ratings

55%

of 29 ratings
Buy
55.2%
Hold
44.8%
Sell
0%

More MRK News

Nasdaq 3d
Is Trending Stock Merck & Co., Inc. a Buy Now?

Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near...

Is Trending Stock Merck & Co., Inc. a Buy Now?
Seeking Alpha 3d
Merck hits secondary goal in late-stage trial for Keytruda in ovarian cancer

Merck (NYSE:MRK) announced on Thursday that its Phase 3 KEYNOTE-B96 trial for its anti-PD-1 therapy Keytruda reached the secondary goal related to the survival...

Merck hits secondary goal in late-stage trial for Keytruda in ovarian cancer
TipRanks 3d
Merck reports Phase 3 ovarian cancer trial meets survival endpoint

Merck (MRK) announced that the Phase 3 KEYNOTE-B96 trial, also known as ENGOT-ov65, met its secondary endpoint of overall survival, or OS, for the treatment of...

Simply Wall St 4d
What Does Merck’s London Research Exit Mean for Its Current Stock Price?

If you are staring at Merck’s stock chart and wondering whether now is the moment to jump in, hold steady, or walk away, you are not alone. Merck’s recent price...

What Does Merck’s London Research Exit Mean for Its Current Stock Price?
Benzinga 4d
Merck's New HIV Treatment Works As Well As Top Drug In Late Trials

The relentless pursuit of innovative treatments in the pharmaceutical industry continues to reshape the landscape of chronic disease management. Merck & Co. Inc...

Merck's New HIV Treatment Works As Well As Top Drug In Late Trials
TipRanks 4d
Merck presents data from Phase 3 studies of doravirine/islatravir

Merck (MRK), known as MSD outside of the U.S. and Canada, announced the presentation of additional data from the Phase 3 studies of the investigational, once-da...

The Motley Fool 5d
Can $10,000 in Merck Stock Turn Into $50,000 by 2030?

The pharmaceutical giant has seen brighter days. Turning $10,000 into $50,000 in about five years would require a compound annual growth rate (CAGR) of almost...

Can $10,000 in Merck Stock Turn Into $50,000 by 2030?

People also own

Based on the portfolios of people who own MRK. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.